RICHMOND, BC, Jan. 10, 2017 /PRNewswire/ – bioLytical Laboratories, a world leader in rapid infectious disease tests, today announced receipt of the prestigious Breakthrough Technology Award from Premier Inc. for its INSTI® HIV-1/HIV-2 rapid point of care diagnostic test. Premier is a healthcare improvement company that unites an alliance of approximately 3,750 hospitals and 130,000 other provider organizations to whom the INSTI HIV test will now been made available at negotiated pricing and terms.
“We are very pleased and proud to receive this award from Premier, and to offer Premier’s members and their healthcare professionals the benefits of our INSTI HIV-1/HIV-2 rapid point of care diagnostic test,” said Livleen Veslemes, bioLytical’s Chief Operating Officer and Chief Financial Officer. “This offering further demonstrates our commitment to improve patient care in the United States and support the CDC guidelines which recommend HIV screening be a part of routine clinical care in all health-care settings.”
Clinicians and other health care system members of Premier selected the innovative INSTI® HIV-1/HIV-2 rapid point of care diagnostic test based on the product’s unique properties and the potential to improve patient care with more routine HIV screening.
bioLytical’s INSTI HIV-1/HIV-2 Rapid Antibody Test is a rapid in vitro qualitative test for the detection of antibodies to Human Immunodeficiency Virus Type 1 and Type 2 in human whole blood, fingerstick blood, or plasma. The test is intended for use by trained personnel in a variety of settings such as hospitals, clinical laboratories, and physician offices as a screening assay capable of providing test results in as little as 60 seconds. The INSTI test kit has a unique immunofiltration “flow-through” design which leads to accelerated and accurate results.